Trading Statement

Pennsylvania--(Marketwire - February 2, 2009) -

PuriCore Pre-Close Trading Update for Year Ended 31 December 2008

Revenues Increased +80% and Cashflow Significantly Improved



MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 2 February 2009 - PuriCore
(LSE: PURI), the life sciences company focused on developing and
commercialising proprietary, green solutions that safely, effectively,
and naturally kill infectious pathogens without causing harm to human
health or the environment, announces its pre-close trading update for
the year ended 31 December 2008. Audited results for this period are
expected to be announced in late April 2009.


2008 Financial Results


  - 2008 sales of USD33.8 million (2007: USD18.6 million) in line
    with market expectations, an increase of 81.1% (85.1% increase on a
    constant currency basis) with record revenues in both core
    businesses:
      - US Food Safety revenue increased 147% to USD19.4 million
      - UK Endoscopy revenue increased 35.2% to USD13.9 million (42.5%
        at constant currency)
  - Gross margins improved to approximately 22.2% (2007: 15.8%)

  - Total selling, general, and administrative expenses reduced
    approximately 10% versus prior year (net of non-cash stock
    compensation)

  - Earnings in line with market expectations

  - Cash outflow from operations halved to approximately USD7 million
    (2007: USD14.1 million)

  - Cash of USD20.7 million at period end


2008 Operational Highlights


  - Major contracts received
      - Safeway, a top-five US supermarket retailer,
        announced the implementation of Sterilox Food Safety Systems
        throughout its North American stores

      - USD11.1 million in contract extensions awarded from the largest
        existing Sterilox Food Safety customers

  - Fundraising completed
      - GBP8.4 million equity (gross) raised in a Placing and Open Offer

      - USD9.7 million raised through issuance of debt

  - Product development: next-generation Sterilox Food Safety System
    launched
  - Sterilox Solution approved for use with organic food by the Organic
    Materials Review Institute


Greg Bosch, Chief Executive of PuriCore, said:"2008 was a strong year for
PuriCore with record revenues in both core
businesses: US Food Safety and UK Endoscopy. We believe that these two
markets -- retail food grocery and non-elective medical procedures --
will be less susceptible to the current challenging economic climate.
Looking ahead, we remain keenly focused on increasing revenue and
improving gross margins while leveraging our operating expenses. These
efforts, combined with our successful equity and debt fund raisings in
2008, leave us well-positioned to execute on our business plan."


Company Results

PuriCore achieved record results for the year with 81% top-line growth
and total revenue of USD33.8 million and significant operating loss
reduction. Excluding the negative impact of the stronger dollar,
revenue grew 85.1% over the prior year. Despite very difficult
financial markets, PuriCore completed two fundraisings during the year:
a Placing and Open Offer raised GBP8.4 million in equity (gross), and
the issuance of debt raised USD9.7 million. Even with the significant
sales growth, PuriCore reduced expenses in both core businesses as well
as in corporate expenses. The Company's cash position at the year end
was USD20.7 million.



Food Safety

PuriCore's Food Safety business in the US achieved outstanding growth,
driven in large part by implementation of Sterilox Systems by the major
national chains. In the second half of the year, PuriCore received a
contract for Safeway's remaining North American supermarkets, marking
the chain-wide implementation for this top-five US supermarket
retailer. Additionally, PuriCore received contract extensions totalling
USD11.1 million from its largest existing Sterilox Food Safety customer,
a top-five US supermarket, and another major Sterilox Food Safety
customer. Late in the year, PuriCore launched its next-generation
Sterilox Food Safety System Model 2200. The Company placed 820 new
Sterilox Food Safety Systems in 2008 bringing its total installed base
to 2,400 Systems, representing approximately 10% of targeted US
supermarkets. PuriCore has further sales opportunities within itsactive
customer base, which in total accounts for nearly 30% of
its 24,000 US target market.


Endoscopy

PuriCore's Sterilox Endoscopy business in the UK also had significant
growth of 43% in 2008 on a constant currency basis. The business grew
at its fastest pace ever despite clearly challenging economic times and
in a relatively mature market. This growth performance was a function
of increased unit placements as well as a focus to develop recurring
revenue streams from lease contracts, service agreements, and related
consumable products. The UK business was also able to achieve this
growth whilst greatly reducing operating expenses throughout the year.


2009 Outlook

PuriCore anticipates profitability in each of its two core businesses
in 2009. These businesses will continue to drive the majority of
PuriCore revenue in 2009 with some early sales in the Wound Care
business. Additionally with reductions already made across the
Company's operating expenses and further diligent cost controls in
place as noted in the Interim Results, PuriCore expects to realize
further cost reductions of approximately 10% in 2009. PuriCore's
2008 year-end cash position of USD20.7 million enables the Company to
execute on its business plan.


Enquiries:

Ben Brewerton        Greg Bosch, CEO
Susan Quigley        Darren Weiss, VP Finance
Financial Dynamics   PuriCore
+44 (0) 20 7831 3113 +1 484 321 2700



About PuriCore

PuriCore plc (LSE: PURI) is a life sciences company focused on
developing and commercialising proprietary green solutions that safely,
effectively, and naturally kill infectious pathogens without causing
harm to human health or the environment. PuriCore's patented,
proprietary technology mimics the human body's production of the
natural antimicrobial hypochlorous acid, offering a safe and
non-hazardous approach to disinfection and sanitisation. The Company's
products are used in a broad range of markets that depend upon
controlling contamination, including retail and foodservice, medical
device disinfection, and wound care. Hypochlorous acid is proven to be
safe, environmentally friendly, and fast acting against a broad range
of infectious pathogens, including major public health threats of M.
tuberculosis, MRSA, E.coli, Norovirus, H5N1 Avian Influenza, HIV,
Salmonella, Polio Virus, Helicobater pylori, and Legionella. PuriCore
is headquartered in Malvern, Pennsylvania, with offices in Stafford,
UK.


To receive additional information on PuriCore, please visit our website
at www.puricore.com, which does not form part of this press release.


Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical facts
but rather are based on the Company's current expectations, estimates,
and projections about its industry; its beliefs; and assumptions. Words
such as
'anticipates,''expects,''intends,''plans,''believes,''seeks,''estimates,'
and similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of
future performance and are subject to known and unknown risks,
uncertainties, and other factors, some of which are beyond the
Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in the
forward-looking statements. The Company cautions shareholders and
prospective shareholders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company only
as of the date of this announcement. The forward-looking statements
made in this announcement relate only to events as of the date on which
the statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these forward-looking
statements to reflect events, circumstances, or unanticipated events
occurring after the date of this announcement except as required by law
or by any appropriate regulatory authority.


All 2008 financials are unaudited.

                    This information is provided by RNS
          The company news service from the London Stock Exchange

END